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In mice, the proviral integration of the Friend Spleen Focus Forming Virus (SFFV) within the PU.1 locus of erythroid
precursors results in the development of erythroleukemia. SFFV integrates several kilobases upstream of the PU.1
transcription initiation start site leading to the constitutive activation of the gene which in turn results in a block of
erythroid differentiation. In this study we have mapped and sequenced the exact location of the retroviral
integration site. We have shown that SFFV integrates downstream of a previously described upstream regulatory
element (URE), precisely 2,976 bp downstream of the URE-distal element. We have also found that SFFV persists
integrated within the same location in resistant cell lines that have lost their differentiation capacity and in which
case PU.1 remains silent. We have examined the methylation status of PU.1 and found that in resistant cells the
nearby CpG islands remained methylated in contrast to a non-methylated status of the parental cell lines.
Treatment with 5-aza-2′-deoxycytidine caused resistant cells to differentiate yet only when combined with HMBA.
Altogether these results strongly suggest that methylation plays a crucial role with regard to PU.1 silencing.
However, although demethylation is required, it is not sufficient to overcome the differentiation impasse. We have
also showed that activation blockage of the Epo/Epo-R pathway remains despite of the absence of PU.1.
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PU.1, the ETS transcription factor encoded by the Sfpi/
PU.1 gene, is crucial for the regulation of hematopoietic
development (Burda et al. 2010). The gene is already
expressed at high levels in multipotential progenitors, in-
cluding erythroblasts. Thereafter, PU.1 expression is tightly
regulated and in mature hematopoietic cells is maintained
in myeloid and B lymphoid cells but not in erythrocytes or
T cells. Like other transcription factors and proteins, PU.1
can posses dual roles and play as an activator or repressor
depending on its combination with variable binding-
partners of each specific cell lineage. PU.1 holds a tumor
suppresor activity during myeloid leukemia by promoting
maturation of myeloid cells but acts as an oncogene when
overexpressed in proerythroblasts by disrupting the eryth-
roid differentiation program (Cook et al. 2004; Moreau-
Gachelin et al. 1996; Rosenbauer et al. 2004).* Correspondence: dbkrimer@cib.csic.es
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reproduction in any medium, provided the origImmortalized murine erythroleukemia (MEL) cells which
are derived from transformed erythroblasts by the Friend
complex virus constitute an appropriate and valuable
model to study tumor cell reprogramming (Moreau-
Gachelin 2006; Papetti and Skoultchi 2007). Insertion of
the Friend spleen focus-forming virus (SFFV) upstream of
the transcription start site of PU.1 leads to constitutive
gene expression and to blockage of erythroid cell differen-
tiation (Ruscetti 1999). MEL cells can be induced to
reinitiate the differentiation program by the addition of
chemical agents such as HMBA, in which case down regu-
lation of PU.1 has been shown to be a critical event that
takes place during early cell differentiation (Rao et al.
1997). We have previously reported on the establishment
of HMBA-resistant cell lines (MEL-R) in which PU.1 re-
mains silent even though the SFFV persists integrated
within a similar location to the site found in MEL parental
lines (Fernández-Nestosa et al. 2008). In this study, we
have further characterized the concrete location of the
SFFV integration site in both, parental and resistant cells,
to confirm that no further changes have occurred in theger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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SFFV integration position in parental and resistant MEL
cell lines is located downstream of the upstream regulatory
element (URE) (Okuno et al. 2005), concretely at 2,976 bp
from the distal element.
We have also studied the methylation status of the
PU.1 promoter and determined that the four CpG
islands close to the PU.1 promoter remain methylated in
MEL-resistant cells in contrast to the non-methylated
status of the parental cell lines.
Materials and methods
Cell cultures
MEL-DS19 and MEL-resistant (MEL-R) cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and
100 units/ml of penicillin and streptomycin (Gibco). Cell
differentiation was induced by exposing logarithmically
growing cell cultures to 5mM of HMBA. MEL-R cells
were routinely cultured in the presence of the differenti-
ation inducer. Hemoglobinized cells were monitored by
determining the proportion of benzidine-staining posi-
tive cells (B+) of cell cultures. In order to analyze the
epigenetic changes of the PU.1 locus, MEL-DS19 and
MEL-R cells were grown in the absence or presence of
0,4 μM or 0,8 μM 5-Aza-2′-deoxycytidine (5-azaC,
Sigma).
PCR analysis
PCR experiments were performed with MEL-DS19 and
MEL-R genomic DNA samples to sequence the viral–
host DNA junction. PCR amplifications were performed
using 200 μM of each nucleotide, 0.4 μM of sense and
antisense primers and 1.25 units of Taq DNA Polymer-
ase (Invitrogen). The PCR program consisted of an ini-
tial denaturation at 95°C during 3 min, followed by 30
consecutive cycles at 94°C during 45 s, annealing at 62°C
during 30 s, extension at 72°C during 30s and a final ex-
tension at 72°C during 10 min. Long-range PCR (LR-
PCR) was performed using the LongRange PCR Kit
(Qiagen) and amplifications were performed using
500 μM of each nucleotide, 0.4 μM of sense and anti-
sense primers and 2 units of LongRange PCR Enzyme
Mix. The LR-PCR conditions comprised: denaturation at
93°C during 3 min, followed by 35 repeated cycles at 93°C
during 15 s, annealing at 62°C during 30 s and extension
at 68°C during 8 min. The following Sfpi-1/PU.1 and
SFFV-specific primers were used: PU.1 Fw: 5′-TCC
GCTCAAGACCAGGTC-3′; PU.1 Rv: 5′-CCATGTAG
CCTTCTGAGT-3′, SFFV 1: 5′-AAGAACAGATGGTC
CCCAGA-3′; SFFV 2: 5′-AAGGCACAGGGTCATTTC
AG-3′; SFFV 3: 5′-AAAGAGCTCACAA CCCCTCA-3′;
SFFV 4: 5′-GCCCAACGTTAGCTGTTTTC-3′; SFFV-a
5′-CAGAACCAGACGCAGGCGCA-3′; SFFV-b 5′-TCCACCATCATGGGGCTTCTCA-3′; SFFV-c 5′-TC
CGCTCAAGACCAGGTC-3′; SFFV-d 5′-AGAGAGGT
GAGAGTCATGCAATG-3′. PCR products were resolved
on agarose gels and visualized by ethidium bromide stain-
ing. The Sfpi-1/PU.1 and virus-specific primers were used
for sequencing which was carried out by Secugen SL (CIB,
Madrid).
Gene expression analysis
Total RNA was isolated from 1 × 107 cells using the
TRIzol (GIBCO BRL) kit following the manufacturer’s
instructions. For the semi-quantitative RT-PCR the reac-
tions consisted of 5 μg of total RNA previously extracted
from the MEL and MEL-R cells, which was reverse tran-
scribed using the M-MLV reverse transcriptase (USB) as
previously has been described (García-Sacristán et al.
2005). PCR amplifications were performed using 200 μM
of each nucleotide, 0.5 μM of the sense and antisense
primers plus 5 units of Recombi-Taq (LINUS). The ampli-
fication conditions encompassed: denaturation at 95°C
during 2 min, followed by 30 cycles of 94°C during 1 min,
annealing during 1 min was carried out at different tem-
peratures depending on the primers used and extension
was undertaken at 72°C during 1 min, with a final exten-
sion at 72°C during 5 min. The annealing temperatures
were 55°C for the Shp1 primer pair and 65°C for the
GAPDH. The following primers were used: Shp1 Fw 5′-
CAGGATGGTGAGGTGGTTT-3′; Shp1 Rv 5 -CTCAA
ACTCCTCCC AGAAG-3′. For the quantitative real time
PCR analysis RNA was isolated from 5 × 106 cells using
the RNeasy Mini Kit (Qiagen) as described by the supplier.
RNA samples were reverse-transcribed using SuperScript®
II Reverse Transcriptase (RT) (Invitrogen). First-strand
cDNA was synthesized from 2.0 μg of total RNA using the
Superscript II (Invitrogen) in a final volume of 20 μl with
0.5 μg of Oligo dT (Invitrogen), 20 units of SUPERase In
RNase Inhibitor (Ambion) and 200 units of Superscript II
reverse transcriptase. The reaction mixture was incubated
at 42°C during 50 min. Quantitative real time PCR
was carried out in iQ5 system (Bio-Rad). The reaction
mixture of 20 μl consisted of 1X iQ SYBR Green
Supermix (Bio-Rad), 1 μl cDNA and 0.2 mM of each
primer. The PCR protocol consisted of: 95°C during 5
min, followed by 50 cycles of 95°C during 30s and
60°C during 30s. The following primers were used:
PU.1 Fwd 5′-GGGATCTGACC AACCTGGA-3′ and
PU.1 Rev 5′-AACCAAGTCATCCGATGGAG-3′. The
relative gene-expression quantification method was
used to calculate the amount of mRNA expression
change according to the comparative Ct method using
β-actin as an endogenous control. Final results were
determined as follows: 2-(ΔCt sample - ΔCt control), where
the ΔCt values of the control and the sample were
determined by subtracting the Ct value of the target
Fernández-Nestosa et al. SpringerPlus 2013, 2:392 Page 3 of 12
http://www.springerplus.com/content/2/1/392gene from the value of the β-actin gene. All experi-
ments were performed in triplicate; differences in cell
input were compensated by normalization against the
β-actin expression levels.
Bisulfite sequencing
Sodium bisulfite conversion was undertaken with the EZ
DNA Methylation-Direct Kit (Zymo Research). The
DNA bisulfite conversion was performed directly from
8 × 104 cells according to the manufacturer’s instruc-
tions. Samples of 2 μl of bisulfite-treated DNAs were
eluted in a 10 μl volume for each PCR reaction.
Converted DNAs were amplified and sequenced by PCR
using primers specific to the bisulfite-converted gDNA
and the ZymoTaq™ DNA Polymerase (Zymo Research).
The PCR protocol used was: 95°C during 10 min,
followed by 35 cycles of 95°C during 30 s, 55°C during
30 s and finally 72°C during 40 s. The set of primers for
bisulfite sequencing PCR (BSP) comprised: PU.1 bis
DNA Fw 5′-GAAAGGAGATAAAATGTGGGAGAT-3′
and PU.1 bis DNA Rv 5′-CCAAATAATCCACTATTCT
TTTAACCT-3′. The PCR products were separated and
visualized in 1% agarose gels, followed by sequencing for
methylation status evaluation. Sequencing was performed
by Secugen SL (CIB, Madrid).
Measurement of DNA methylation by pyrosequencing
Sodium bisulfite modification of 0.5 μg of genomic DNA
isolated from MEL-DS19 and MEL-R was carried out
with the EZ DNA Methylation Kit (Zymo Reserch) follow-
ing the manufacturer’s protocol. Samples of 2 μl bisulfite-
treated DNA were eluted in a 15 μl volume for each PCR
reaction. The region of interest was amplified by PCR
using primers specific to the bisulfite-converted gDNA.
As a control, the efficiency of the bisulfite conversion was
assessed using primers for the non-converted DNA se-
quence. Pyrosequencing was performed using the follow-
ing primers: Fw 5′-AGTTTGGTAGTTTTGGGATTAA
AG-3′; Rev 5′ [Btn] ATTTCTTCTCAATCCCCTCT
AA-3′; seq 5′-AAATTTATTTTTAAAATTAGGGA-3′.
Pyrosequencing reactions and methylation quantification
were performed in a PyroMark Q24 System version 2.0.6
(Qiagen). Graphic representation of methylation values
showed bars identifying CpG sites that represented
methylation percentages. Assay design reports, which in-
clude the target sequence region and primer sequences,
are provided as Additional file 1.
Plasmid construction and DNA transfections
The PU.1-ER construct was generated by PCR using the
Expand High Fidelity PCR System (Roche) to amplify the
cDNA of PU.1 derived from MEL-DS19 cells. The primers
contained BamHI recognition sites and consisted of the
following sequences: PU.1-ER Fw 5′-GGGGCACCTGGTCCTGAG-3′ and PU.1-ER Rv 5′-CGCGGATCCGAG
TGGGGCGGGAGGCG-3′. The expression vector produ-
cing the PU.1-ER fusion protein was constructed by
subcloning the 869 bp BamHI fragment encoding the
PU.1 cDNA into the pEBBpuro ER vector digested with
the same enzyme. The inducible vector pEBBpuro GATA-
1-ER (a generous gift from A. Skoultchi) was used to pro-
duce the conditionally active form of GATA-1. Stable
transfectants of MEL-R were prepared as described previ-
ously (Vanegas et al. 2003). In short, recombinant DNA
was introduced into exponentially growing MEL cells
by lipofectine (Gibco) and after a 6 h incubation
period cells were distributed into 96-well plates. The
transfectants were selected and maintained in growth
medium containing 5 μg/ml puromycin. Cell differen-
tiation was tested by cell culture in the absence or
presence of 5 mM HMBA with or without 10−7 M β-
estradiol. Cell growth was measured on a daily basis
by aliquot counting of the cultures with a Neubauer
hemocytometer chamber.
Antibodies and immunoblot analysis
MEL and MEL-R cells (1 × 107) were pelleted, washed twice
with cold PBS and lysed with Laemmli buffer (65 mM
Tris–HCl pH 6.8, 10% glycerol, 5% 2-mercaptoethanol,
1% SDS) containing protease inhibitors (SIGMA). Proteins
(20–50 μg) were resolved in a 10% SDS-polyacrylamide
gel electrophoresis and transferred to PVDF membranes
(Millipore). Primary antibodies included rabbit polyclonal
anti-Sat1 antibody (1:1,000 Cell Signaling), rabbit poly-
clonal anti-Phospho-Sat1(Tyr 701) antibody (1:1,000 Cell
Signaling), rabbit polyclonal anti-PU1 antibody (1:1,000;
Santa Cruz) and mouse monoclonal anti-α-Tubulin anti-
body (1:10,000, Sigma).
Results
Mapping the SFFV integration site within the PU.1 locus
of MEL and MEL-R cell lines
The Friend spleen focus-forming virus (SFFV) comprises
a replication-defective retrovirus that in cooperation with
the murine leukemia virus (MuLV) causes erythroleuke-
mia in mice (revised in (Moreau-Gachelin 2006; Ruscetti
1999)). SFFV induces transformation of proerythroblasts
by insertional mutagenesis into the PU.1 locus which leads
to the constitutive activation of the gene. Earlier studies
have identified the SFFV proviral integration in a concrete
region adjacent to the PU.1 (also called Sfpi-1 or Spi-1)
gene (Moreau-Gachelin et al. 1988; Paul et al. 1989). More
recently, integration of the SFFV was delimited to the
URE located 14 kb upstream of the PU.1 transcription
start site (Okuno et al. 2005). Previously, we had used
Southern blotting to show that SFFV integration occurs at
a similar location in both MEL and MEL-R clones
(Fernández-Nestosa et al. 2008). To determine the exact
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employed a PCR approach using primer pairs of the pro-
viral LTR (long terminal repeat), SFFV-genome specific
and PU.1-specific sequences of upstream regions. After
several attempts we ended up with primer pairs which
amplified products derived from both of the putative
SFFV-PU.1 junction ends. Subsequently we used nested
primers for a second round of PCR amplification followed
by fragment isolation and sequencing (Figure 1A and B).
After identification of both SFFV-PU.1 junction ends, a
Long range-PCR (LR-PCR) reaction was carried out using
the reverse and forward PU.1 primers (Figure 1C). Two
bands of 6,854 bp and 564 bp, corresponding respectively
to the integrated SFFV and the wild type alleles, were
amplified in both cell lines (MEL and MEL-R). Re-
sults for MEL-R cells are shown in Additional file 1:
Figure S1. Figure 2A represents the PU.1 locus drawn
to scale displaying the upstream localization of the
SFFV genome. A total of 9,584 bp separate the closest
SFFV long terminal repeat from the functional ATG
of PU.1, while 2,976 bp divide the proviral distant
long terminal repeat and the 3.4 kb HindIII-fragment
containing the URE. Our results have clearly shown
that the SFFV genome integration into the PU.1 locus
occurred outside of the URE. We have also confirmed
that the provirus is integrated in an opposite tran-
scriptional orientation as related to that of the PU.1
locus (Additional file 1: Figure S2).A
B
1 2- 43
588 bp
420 bp
591 bp
443 bp
SFFV
1 2
Sfpi-PU.1 locus
3 4
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Figure 1 PCR probe to confirm the SFFV integration site within the P
using MEL genomic DNA as a template. Black arrows over the SFFV genom
SFFV-PU.1 junctions. Odd numbers 1 and 3 represent the primers used to i
represent the primers used for the downstream integration. Number 5 rep
complete SFFV integration. Black boxes correspond to the five exons of PU
direction of translation. B) Agarose gel electrophoresis performed using the
LR-PCR probe to confirm SFFV integration; both the wild type (564 bp) andReactivation of the silenced PU.1 locus of MEL-R cells by
5-azaC treatment
A major difference detected between leukemia HMBA-
resistant cells and their parental MEL cells comprised
the unexpected inactivation of PU.1 in MEL-R cell lines
(Fernández-Nestosa et al. 2008). Furthermore, treatment
with 5-Aza-2′-deoxycytidine (5-azaC) while not with
trichostatin A (TSA) triggered PU.1 expression in all
MEL-R clones. Since 5-azaC acts as an inhibitor of
methylation maintenance (Christman 2002) it has been
suggested that the activation of PU.1 expression in
MEL-R is caused by a DNA methylation status change.
We have performed in the present study a quantitative
analysis regarding relative PU.1 expression in both resist-
ant and parental cell lines as well as in cells after treat-
ment with 5-azaC. Quantitative real-time RT-PCR (qRT-
PCR) was first used to analyze the relative PU.1 mRNA
expression in MEL and MEL-R (Figure 3A). We found
that transcripts for PU.1 were expressed a several fold
higher in MEL cells compared to the resistant cell lines.
Cell exposure to 5-azaC caused a circa 200-fold increase
of PU.1 mRNA expression in MEL-R cells (Figure 3B).
On the contrary, a ~3 fold increase in PU.1 mRNA
was observed during the course of MEL differentiation
when cells were cultured in the presence of HMBA; no
significant difference was detected in the non-induced
(−HMBA) MEL cells (Figure 3C). Nevertheless, PU.1
mRNA levels of MEL-R cells treated with 5-azaC never5-
C
6859 bp
564 bp
U.1 locus. A) Illustration of the multiple verification PCR amplifications
e (gray box) indicate the pair of primers designed to amplify the
dentify the upstream integration junction and even numbers 2 and 4
resents the long-range PCR (LR-PCR) used as a probe to confirm the
.1; the arrow above exon number one represents the initiation and
primers schematized in A). C) Agarose gel electrophoresis of the
the integrated allele (6,859 bp) are visualized.
Figure 2 Map of the PU.1 genomic region showing the location and orientation of the SFFV proviral integration in MEL-DS19
cells. A) Diagram (drawn to scale) of the MEL-DS19 PU.1 genomic locus showing the location of a 3.4-kb HindIII (H) fragment referred
to as the kb-14 URE (Upstream Regulatory Element) (Okuno et al. 2005), the SFFV genome is integrated downstream of the URE
(gray box flanked by white boxes that symbolize the viral “long terminal repeats” (L)), and the five coding exons (black boxes) of the
PU.1 locus. The sequences drawn below represent the upstream and downstream viral–host junctions, respectively. B) and C) Sequence
alignment of the SFFV integration site displaying the PU.1 genomic sequences of mouse and of the MEL-DS19 cell line together with
the SFFV genomic sequence. The PU.1 genomic sequence of the MEL-DS19 cell line corresponds to the upstream (B) and downstream
(C) viral–host junction. Viral-host junctions as indicated in A) are underlined.
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shown that PU.1 expression was boosted by 5-azaC appli-
cation to MEL-R cells yet transcription activity was much
lower in the non-induced and not differentiated MEL
cells.MEL
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Figure 3 Reactivation of the silenced PU.1 locus by 5-azaC treatment
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calculated using the ΔΔCt method. Each value is the average of three readMethylation status of CpG islands at the PU.1 promoter
CpG islands consist of genomic regions characterized by a
high content of CpG dinucleotides, usually unmethylated
and associated to most known transcription starting sites
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Our previous results have shown a PU.1 gene expression
increases after treatment with 5-azaC in differentiated
MEL cells, but in particular in MEL-R clones ((Fernández-
Nestosa et al. 2008) and the present study). To explore
changes in the methylation status of the PU.1 promoter
that would eventually lead to DNA silencing we have used
a bisulfite conversion followed by DNA sequencing of the
PU.1 promoter region which comprises four CpG islands
(Shearstone et al. 2011) (Figure 4). We first confirmed that
all the sites of the non-CpG cytosine islands were
displayed as thymines, which implied that the bisulfite-
induced conversion of unmethylated cytosines to uracil
in our samples was all-encompassing (Additional file 1:
Figure S3). The analysis confirmed that in MEL-R cells all
four CpG islands remained stably methylated, while in the
MEL parental cell lines the conversion of the four cyto-
sines (Cs) into thymines (Ts) revealed the unmethylated
status. When we analyzed in detail the chromatogram
sequence we observed some overlapping of Cs and Ts at
individual peaks of CpG implying partial methylation. As
differentiation proceeds under HMBA treatment a more
pronounce overlapping is observed (Additional file 1:
Figure S4). To quantify the DNA methylation levels we
preceded to bisulfite pyrosequencing using the sets of
primers for PCR amplification described by Shearstone
et al. (2011) (Shearstone et al. 2011), which allow for the
analysis of the first three CpG islands of the PU.1 pro-
moter (Figure 5). The results showed that more than 80%
of CpG1, CpG2 and CpG3 were methylated in MEL-R
cells in contrast to only 40% methylation observed for theA
B
MEL
MEL-R
Figure 4 Methylation status of the PU.1 promoter region. A) DNA chro
genomic DNA derived from MEL and MEL-R cell lines. Red circles highlight
changed to thymines in the MEL-DS19 cell line after bisulfite treatment. B)
genomic DNA from A). The CG sequences were numbered according to (SMEL progenitor cells. Taken together, these experiments
confirmed that the PU.1 promoter is methylated in MEL-R
cells, which moreover suggests that this methylation status
might contribute to PU.1 silencing in these cell lines.
5-azaC treatment induces MEL-R cell differentiation in the
presence of HMBA
We hypothesized that cell differentiation might follow
demethylation as had previously been shown in MEL
progenitor cells (unpublished results). To address the
potential of 5-azaC to induce differentiation of MEL-R
cultures, we treated cells with two different concentra-
tions of 5-azaC (which do not compromise cell viability,
unpublished results) in the presence or absence of 5mM
HMBA. Percentage of cell differentiation was measured
counting benzidine positive cells at different time points
(Figure 6). The results clearly showed that 5-azaC alone
was unable to induce cell differentiation given the in-
significant proportion of B + cells present in the MEL-R
cultures treated with 0.4 or 0.8 μM 5-azaC. On the con-
trary, when HMBA was used in combination with 5-azaC
a substantial proportion differentiated reaching B + cells a
proportion of about 30% after 144 hours of treatment.
Altogether, these data have demonstrated that demethyla-
tion is necessary but not sufficient to overcome the differ-
entiation blockage. However, removal of methylation
marks would result in a receptive chromatin status and
lead inducers such as HMBA, that by themselves have no
effect on MEL-R differentiation ((Fernández-Nestosa et al.
2008) and Figure 6), to trigger cells to resume the differen-
tiation program.matogram of the PU.1 upstream region using bisulfite-treated
the cytosines of the four CpG islands of the MEL-R cell line that
Methylation analysis of the PCR products of the bisulfite-treated
hearstone et al. 2011) and their methylation status was determined.
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Figure 5 DNA methylation status of the PU.1 locus regulatory region. A) A genomic map (not drawn to scale) depicts the regions
containing the analyzed CpGs. The CpG colored in blue represent PCR amplified islands which however were not detected by the sequencing
primers. CpG colored in red represent sequenced islands. B) Individual CpG methylation percentages of MEL DS19 and MEL-R cell lines.
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yet is not required to induce MEL-R cell differentiation
Our results have shown that treatment with 5-azaC acti-
vated PU.1 expression and together with HMBA induced
erythroid differentiation of MEL-R cultures (Figure 3 and72 hr 96 hr
%
 B
+ 
ce
lls
0
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Aza 0.4 M
Aza 0.8 M
Aza 0.4 M + HMBA
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Figure 6 Treatment with 5-azaC induces MEL-R cells to differentiate i
determined by the benzidine assay. Cells were cultured in the absence or p
HMBA. Each bar indicates the mean and standard deviation of three indep(Fernández-Nestosa et al. 2008)). We hypothesized that
PU.1 might be necessary for erythroleukemia cells to dif-
ferentiate and therefore, restoring PU.1 function in MEL-R
cells would bring back the induced-differentiation potential
to these cell lines. In order to overexpress PU.1 we generated120 hr 144 hr
n presence of HMBA. Percentage of differentiation of MEL-R cells was
resence of different concentrations of 5-azaC, with or without 5 mM
endent experiments.
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http://www.springerplus.com/content/2/1/392a stable transfection introducing vector containing a con-
ditional PU.1 fused to the ligand-binding domain of the
estrogen receptor (PU.1-ER) in order to carry out the
transformation of MEL-R cells. Puromycin-resistant
clones were isolated by a limited dilution and analyzed
for the expression of the chimeric PU.1-ER protein
(Figure 7A). We next looked for the ectopic PU.1 expres-
sion effect on the production of B + cells when transfectants
were grown in the presence of β-estradiol and HMBA
(Figure 7B). A conditional GATA1-ER clone (Fernández-
Nestosa et al. 2008) was used as the control. The results
have shown that forced expression of PU.1 is unable to
trigger MEL-R cell differentiation. In all of the transfectant
strains analyzed, PU.1-ER3, PU.1-ER7 and PU.1-ER8, thePU.1-ER
α-Tubulin
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Figure 7 Ectopic expression of PU.1 restricts the proliferative capacity
blot analysis of lysates derived from MEL-R PU.1-ER transfectants stimulated
by SDS-polyacrylamide gel electrophoresis and analyzed by immunoblottin
different clones. B) Percentage of benzidine positive cells (B+) in PU.1 and
the presence of 5 mM HMBA. Each bar indicates the mean and standard d
were cultured in the presence or absence of β-estradiol and cell counts wepercentage of B + cells observed consisted of very low
values (less than 1%) in line with the mock. On the con-
trary, cell growth was markedly reduced in all of the ana-
lyzed transfectants, with the reduction being more
pronounced commencing 24 hours after activation of
PU.1 (Figure 7C). These results are consistent with previ-
ous reports on MEL (Yamada et al. 1997) and other cell
lines for which PU.1 was shown to induce growth arrest
and apoptosis.
MEL-R cells show similar expression levels of tyrosine
phosphatase Shp-1 as those of the progenitor MEL cell lines
Previous work in Dr. Ruscetti’s lab had shown that the
inappropriate expression of PU.1 in SFFV-infectedP-E
R87
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Gata1-ER9
PU.1-ER8
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2 hr
PU.1-ER3
PU.1-ER7
PU.1-ER8
PU.1-ER3 + β-estradiol
PU.1-ER7 + β-estradiol
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but is unable to induce MEL-R cell differentiation. A) Western
with β-estradiol. Equal amounts of protein (50 μg) were fractionated
g with an anti-PU.1 antibody. Numbers above the panel correspond to
GATA-1 stable transfectants activated by β-estradiol and cultured in
eviation of three independent experiments. C) PU.1-ER transfectants
re recorded at the indicated times.
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Shp-1 levels which influence some signaling components
of the Epo/EpoR pathway (revised in (Cmarik and
Ruscetti 2010)). Particularly important was the block of
the erythropoietin-induced Stat1/3 phosphorylation
resulting in an obstruction of the DNA binding capacity,
which in turn is crucial for erythroid differentiation
(Nishigaki et al. 2006). Given that MEL-R differentiation
blockage is independent of PU.1 overexpression, it is
highly unlikely that the impediment to differentiate
would reside in the inactivation of the Stat proteins
through tyrosine dephosphorylation by SHP-1. In order
to test whether the Stat1 inactivation occurred in MEL-
R cell lines we performed a Western blot analysis using
an anti-phospho-Stat1 antibody, which detects the phos-
phorylated tyrosine 701 of the α and β isoforms of Stat1
(Figure 8A). We distinguished two bands of 84 and 91
kDa corresponding to the α and β Stat isoforms, respect-
ively, after stimulation with IFN-α of MEL and MEL-R
cell lines. On the contrary, we failed to detect phosphor-
ylated Stat1 neither before nor after treatment with Epo.
We also compared the phosphatase Shp-1expression
levels of the MEL-R and MEL differentiation- induced
cell lines (Figure 8B). We found that Shp-1 was highly
expressed in the non-induced MEL cells (0 hr) and also
in the MEL-R cells, yet rapidly declined as the cells
underwent differentiation in response to HMBA (48 and
96 hr). Altogether, these results suggest that although
Shp-1 could be related to the differentiation blockage of
MEL-R cells, nonetheless, it is a PU.1-independent
process.
Discussion
SFFV integration within the PU.1 locus of MEL and MEL-R
cell lines
PU.1 proviral insertion is a major event that occurs dur-
ing the second stage of the Friend disease and which
leads to a block of the erythroid differentiation program.
It was initially recognized that SFFV integrates upstream
of the PU.1 transcriptional start site (Moreau-Gachelin
et al. 1989; Paul et al. 1989) and later on the target for
SFFV integration was precisely located at −14 kb of thepSTAT1α
C CEpo IFN-αIFN-α Epo
MEL MEL-R
STAT1
pSTAT1β
A
Figure 8 STAT1 tyrosine phosphorylation analysis of MEL DS19 and M
erythroleukemia cells (C) and stimulated with erythropoietin (100 U/ml) (Ep
immunoblotted with either anti-phospho-STAT1 (tyrosine 701) (upper pane
expression by semi-quantitative RT-PCR of the parental MEL cells untreated
cells (R). PCR products were normalized to GAPDH, separated by electrophURE in a non-conserved 500-bp spacer, lying exactly
between two highly conserved homologous regions
(Okuno et al. 2005). The mechanism by which SFFV
induces permanent PU.1 expression in erythroleukemia
cells was suggested to rely on the disruption of the URE at
the non-homologous spacer. This interruption might
prevent the 5′ distal region to down-regulate PU.1 expres-
sion, while the 3′ proximal element constitutively activates
PU.1 transcription. In this study, we have identified, at the
nucleotide level, the exact location of the SFFV integration
site within the PU.1 locus of erythroleukemia cells. We
provide proof that the integration site resides outside of
the URE, concretely 2,976 bp apart, which therefore ex-
cludes the hypothesis of the negative/positive regulation
of the URE 5′ proximal/3′ distal regions, respectively. In-
stead, it seems that the SFFV integration might block a
negative regulation of the URE on the PU.1 promoter
which together with the transcriptional enhancer elements
supplied by the SFFV long terminal repeats (LTR) result
in an unsolicited activation of the gene. On the other
hand, as was predicted in our previous study (Fernández-
Nestosa et al. 2008), the SFFV insertion of the resistant
cell lines (MEL-R) occupied an identical position com-
pared to the parental cell lines. This observation rules out
the possibility that PU.1 silencing in MEL-R cells may well
be a consequence of either the absence of SFFV or that
proviral integration might have occurred at a different
spot.
These findings are focused on the MEL-DS19 cell line
derived from the MELC 745A strain, which in turn de-
rives from an original Charlotte Friend’s lab strain (Ohta
et al. 1976). Therefore, these results do not preclude the
integration of SFFV at a different site of the PU.1 locus
in other host genomes. Many models for the selection of
integration-sites by a retrovirus favor their integration
near to DNase I-hypersensitive sites characterized by an
open chromatin conformation (Lewinski et al. 2006).
Genome mapping has allowed the detection of putative
SFFV integration sites extended over several kilobases
upstream of the PU.1 coding region (Moreau-Gachelin
et al. 1988; Paul et al. 1991). Proviral insertion at the
5′ end of the PU.1 locus has also been described in0 48 96 R
MEL
Shp-1
GAPDH
B
EL-R cell lines. A) Non-stimulated MEL DS19 and MEL-R
o) or interferon α (IFN-α) (500 U/ml). Total cell lysates were
l) or anti-STAT1 antibody (lower panel). B) Comparison of Shp-1
(0) or treated with HMBA during 48 or 96 hours (48, 96) and of MEL-R
oresis in a 1% agarose gel and stained with ethidium bromide.
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et al. 2012; Hasegawa et al. 2005). In this study we have
identified and sequenced the genome-viral junction region
of MEL-DS19 and MEL-R clones and plan to further ex-
tend a similar approach to other SFFV-infected cell lines.
Finally, novel cis-regulatory elements outside of the URE,
about 10kb upstream of the PU.1 transcriptional start site,
have recently been described (Zarnegar et al. 2010). These
elements can simultaneously act as enhancers in myeloid
cells and repressors in T cells and sometimes have been
described to neutralize the continuous URE enhancer
function. These newly characterized elements overlap with
the SFFV integration site described in this report and sug-
gest other possible mechanisms that can mediate PU.1
regulation.
Methylation suppressed PU.1 expression of MEL-R cells
In this study we have demonstrated that 5′-CpG-3′
dinucleotides of the PU.1 promoter region are highly
methylated in MEL-R cells, but not in the parental
MEL-DS19 cell line. DNA methylation of CpG dinucleo-
tides comprises one of the best characterized epigenetic
marks that condition gene expression, usually producing
a repressive transcription status with consequent gene
silencing (Jones 2012). Analysis of the four CpG islands
of the PU.1 promoter (Shearstone et al. 2011) showed a
high level of methylation in MEL-R cells compared to
the MEL parental cell lines. This hypermethylation could
be responsible for the PU.1 inactivation of the resistant
clones. Accordingly, reversal of this hypermethylated
status caused by treatments with 5-azaC, a known antag-
onist of DNA methylases (Christman 2002), that have
been reported to restore PU.1 expression (Amaravadi
and Klemsz 1999; Tatetsu et al. 2007) induced the differ-
entiation of MEL-R cell cultures. On the other hand,
methylation of PU.1 in the MEL-DS19 cells was signifi-
cantly lower than in MEL-R cell lines and the adding of
5-azaC to the cultures produced only minor alterations.
The HMBA-induced differentiation did not modify the
methylation status of PU.1 in the parental cell lines, as
would have been expected based on the gradual silen-
cing of PU.1 through erythroid differentiation. This truly
represents a paradox as methylation prevents PU.1 ex-
pression in MEL-R cells leading to gene silencing and
differentiation blockage. However, the gradual silencing
of PU.1 during HMBA-induced erythroid differentiation
has been reported not to consist of a methylation-
related process (Shearstone et al. 2011). It has recently
been reported that global DNA demethylation occurs
continuously during mouse erythropoiesis in vivo, a
process which is also associated to DNA replication and
has been suggested to take place during differentiation
of most somatic cells. The observed MEL-DS19 cell line
PU.1 methylation status harmonizes with this model,even in the case of the HMBA-induced differentiation
for which methylation of PU.1 is limited. On the con-
trary, PU.1 methylation of MEL-R clones follows the
classical methylation concept as a robust mechanism for
gene silencing. After methylation mark removal, PU.1
expression is restored and MEL-R cells become receptive
to HMBA. This places emphasis on another controversy
concerning the role of PU.1 in erythroleukemia cells.
Differentiation blockage in murine erythroleukemia cells
has been attributed to the inopportune expression of
PU.1 (Rao et al. 1997). Erythroid differentiation is also
partially blocked in PU.1 transgenic proerythroblasts
(Moreau-Gachelin et al. 1996). However, previous find-
ings have indicated a requirement of PU.1 expression for
erythroid differentiation, Rosenbauer and coworkers dem-
onstrated that the gradual activity reduction of PU.1, ra-
ther than the complete loss, can induce acute myeloid
leukemia (AML) in mice (Rosenbauer et al. 2004). Two re-
cent reports (Wontakal et al. 2011; Ridinger-Saison et al.
2012), on the other hand, have revealed the complexity of
the pathways regulated by PU.1 in several hematopoietic
lineages. PU.1 level differences are crucial for cell identity
and even low concentrations of the protein can promote
ubiquitous cellular functions (Wontakal et al. 2011).
Altogether, these findings suggest that PU.1 is necessary
for erythroid commitment, but contrasts with the
downregulation requirement for terminal differentiation
(Atar and Levi 2005; Rao et al. 1997; Yamada et al. 1997).
PU.1 expression is abolished in the HMBA-resistant
erythroleukemia cells and yet these cells are unable to dif-
ferentiate (this study and (Fernández-Nestosa et al. 2008)).
Low PU.1 levels might be necessary for erythroleukemia
cells to differentiate, as probably is the case of MEL-DS19
cells. MEL-R cell lines, on the contrary, had a completely
blocked (methylated) PU.1 expression and had lost their
ability to respond to HMBA, a process that we have
shown to be reversible by demethylating agents. We also
observed that the expression of PU.1 driven by a condi-
tional estrogen-activated element led to cell growth arrest
and apoptosis, in agreement with earlier findings of MEL,
K562 leukemia and myeloma cell lines (Aoyama et al.
2012; Tatetsu et al. 2007; Yamada et al. 1997). However,
the ectopic expression of PU.1 could not have triggered
the differentiation of MEL-R cells. It is most likely that
additional factors, essential for erythroid differentiation,
might have also been epigenetically silenced in resistant
cell lines.
STAT-1 phosphorylation blockage of MEL-R cells was
independent of PU.1 expression
In addition to the ability of PU.1 to block erythroid ter-
minal differentiation by antagonism with GATA-1, the
locus mechanism of action may also apply to the activa-
tion of SHP-1. Previous work had already shown that
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ation, thus preventing the binding activity and blocking
erythroid differentiation in SFFV-transformed erythro-
leukemia cell lines (Nishigaki et al. 2006). It has also
been shown that SHP-1 expression is significantly re-
duced in PU.1−/− erythroid cells (Fisher et al. 2004). This
data suggests that high PU.1 levels block differentiation
signals although in an indirect way. We have observed
that in MEL-DS19 cells, STAT1 α and β are neither
tyrosine phosphorylated before nor after stimulation
with erythropoietin (Epo). In addition, we also showed
that SHP-1 was highly expressed in parental cell lines;
nonetheless the expression was significantly reduced
during the HMBA-induced differentiation. Unexpect-
edly, we have also noticed a failure of STAT1 to become
phosphorylated in Epo-stimulated MEL-R cells in which
PU.1 expression was completely abolished by DNA
methylation. HMBA-resistant cell lines also showed a
high SHP-1 expression. These results strongly suggest
that in MEL-R cells the blocking of the STAT1 DNA
binding activity is regulated by a different mechanism.
Additional file
Additional file 1: Figure S1. PCR confirmation of the SFFV integration
site at the PU.1 locus in MEL-R cells. A) Illustration of PCRs performed
using MEL-R genomic DNA as a template (see legend of Figure 1 details).
B) Upstream and downstream confirmation PCRs. C) LR-PCR confirmation
using MEL and MEL-R genomic DNA. Figure S2. Orientation of the SFFV
provirus relative to the transcriptional direction of the PU.1 gene. A)
Schematic drawing of the PU.1 locus showing the potential
transcriptional orientation of the SFFV genome relative to the PU.1
transcript. Horizontal arrows indicate primers designed to confirm the
direction of proviral integration. Arrows above exon 1 of PU.1 and above
the SFFV genome indicate the transcriptional orientation. c and d
represent upstream and downstream primers, respectively, of the PU.1
locus. a and b indicate the SFFV genome specific primers. B) and C) PCR
products obtained using different combinations of PU.1 and SFFV primers
in MEL (B) and MEL-R (C); cb amplified a 1,765 bp and ad a 1,744 bp
fragment, respectively. Figure S3. Specific demethylation at CpG
dinucleotides of the PU.1 upstream regulatory region of MEL-DS19 and
MEL-R. A) Genomic region from the PU.1 upstream locus that includes
the bisulfite converted region (bold) with the four CpG dinucleotides
(red) as described in (Shearstone et al. 2011). Underlined sequences
correspond to the primers used for pyrosequencing. B) Alignment of a
187 bp fragment amplified after bisulfite conversion in MEL-DS19 (BSP-
MEL) and MEL-R (BSP-MEL-R); the same fragment of the mouse genome
(gDNA) is included as a comparison. In red, unchanged Cs after bisulfite,
in blue Cs changed to Ts. Figure S4. Methylation status of the PU.1
promoter region in HMBA treated cells during 48 and 96hr, respectively.
Red circles highlight the cytosines of the four CpGs. N represents the
positions where the C and T peaks overlapped.Competing interests
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